Association of signaling proteins with a nonmitogenic heterodimeric complex composed of epidermal growth factor receptor and kinase-inactive p185(c-neu)

被引:11
作者
Dougall, WC
Qian, XL
Miller, MJ
Greene, MI
机构
[1] UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,CTR RECEPTOR BIOL,PHILADELPHIA,PA 19104
[2] UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,DIV IMMUNOL,PHILADELPHIA,PA 19104
关键词
D O I
10.1089/dna.1996.15.31
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The functional consequences of heterodimer formation between the epidermal growth factor receptor (EGFr) and the p185(c-neu) receptor tyrosine kinase include increased mitogenic and transformation potencies, To determine the possible alteration of signal transduction pathways resulting from this heteromeric complex, the capacity of several signaling proteins to associate with the heterodimeric receptors has been assayed, The in vivo interaction with the EGFr/pl85(c-neu) heterodimer of several signal transduction proteins, including phospholipase C-gamma 1 (PLC-gamma 1), the p85 subunit of phosphotidylinositol 3-kinase, the ras GTPase activating protein, SHC, NCK, p72RAF, and the tyrosine phosphatase SHPTP2, was measured by coimmunoprecipitation. The binding of these signaling proteins to a complex composed of EGFr and a kinase-inactive form of p185 (p185K757M) was not impaired, even though the mitogenic and transformation activity of this complex had been abrogated. In addition, the EGF-induced phosphorylation of GAP, p85, and PLC-gamma 1 did not correlate with the dominant-negative action of p185K757M on EGFr function, Thus, substrate association and phosphorylation do not correlate stringently with the mitogenic and transforming activity of this receptor complex, suggesting additional pathways or mechanisms vital to EGFr/pl85(c-neu) heterodimeric signaling.
引用
收藏
页码:31 / 40
页数:10
相关论文
共 52 条
[1]   ONCOGENIC ACTIVATION OF THE NEU-ENCODED RECEPTOR PROTEIN BY POINT MUTATION AND DELETION [J].
BARGMANN, CI ;
WEINBERG, RA .
EMBO JOURNAL, 1988, 7 (07) :2043-2052
[2]   A SINGLE AUTOPHOSPHORYLATION SITE CONFERS ONCOGENICITY TO THE NEU/ERBB-2 RECEPTOR AND ENABLES COUPLING TO THE MAP KINASE PATHWAY [J].
BENLEVY, R ;
PATERSON, HF ;
MARSHALL, CJ ;
YARDEN, Y .
EMBO JOURNAL, 1994, 13 (14) :3302-3311
[3]  
CAMPOSGONZALEZ R, 1992, J BIOL CHEM, V267, P14535
[4]   A NEU ACQUAINTANCE FOR ERBB3 AND ERBB4 - A ROLE FOR RECEPTOR HETERODIMERIZATION IN GROWTH SIGNALING [J].
CARRAWAY, KL ;
CANTLEY, LC .
CELL, 1994, 78 (01) :5-8
[5]  
CHAZIN VR, 1992, ONCOGENE, V7, P1859
[6]   THE CARBOXY-TERMINAL DOMAINS OF ERBB-2 AND EPIDERMAL GROWTH-FACTOR RECEPTOR EXERT DIFFERENT REGULATORY EFFECTS ON INTRINSIC RECEPTOR TYROSINE KINASE FUNCTION AND TRANSFORMING ACTIVITY [J].
DIFIORE, PP ;
SEGATTO, O ;
LONARDO, F ;
FAZIOLI, F ;
PIERCE, JH ;
AARONSON, SA .
MOLECULAR AND CELLULAR BIOLOGY, 1990, 10 (06) :2749-2756
[7]   ERBB-2 IS A POTENT ONCOGENE WHEN OVEREXPRESSED IN NIH/3T3 CELLS [J].
DIFIORE, PP ;
PIERCE, JH ;
KRAUS, MH ;
SEGATTO, O ;
KING, CR ;
AARONSON, SA .
SCIENCE, 1987, 237 (4811) :178-182
[8]  
DIGUGLIEMO GM, 1994, EMBO J, V13, P3302
[9]  
DOUGALL WC, 1994, ONCOGENE, V9, P2109
[10]   MONOCLONAL-ANTIBODIES IDENTIFY A CELL-SURFACE ANTIGEN ASSOCIATED WITH AN ACTIVATED CELLULAR ONCOGENE [J].
DREBIN, JA ;
STERN, DF ;
LINK, VC ;
WEINBERG, RA ;
GREENE, MI .
NATURE, 1984, 312 (5994) :545-548